Alfa Aesar joins Thermo Fisher Scientific

Published: 1-Oct-2015
Ingredients Finance

Johnson Matthey completes the £256m transaction to sell its research chemicals business to US life science supplier


Alfa Aesar is now part of Thermo Fisher Scientific following the completion of Johnson Matthey's cash £256m sale of the research chemicals business.

The transaction was first announced on 25 June.

Alfa Aesar is a supplier of more than 46,000 speciality chemicals to both industry and academic institutions in small-scale research quantities.

Commenting on the deal, Robert MacLeod, Chief Executive of Johnson Matthey, said: 'The divestment of the research chemicals business is a further step in delivering our long-term strategy to focus the group on growth areas where we can apply our expertise in complex chemistry to create long term value for our shareholders.'

  • Companies:
  • Johnson Matthey
  • Thermo Fisher Scientific
See more

You may also like

Hi Tech Manufacturing

Johnson Matthey agrees to sell Medical Device Components business

Read more
The business has been sold to Montagu Private Equity for USD $700m

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Berry Global invests to increase production capacity for healthcare products Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
  3. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets
  4. Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).
  5. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Hi Tech Manufacturing

Johnson Matthey agrees to sell Medical Device Components business

The business has been sold to Montagu Private Equity for USD $700m
Ingredients

Thermo Fisher Scientific launches next-generation Invitrogen TaqMan Cells-to-CT Express Kit with simplified, more sustainable workflow

With the Cells-to-CT Express Kit, researchers can measure relative gene expression while skipping the traditional RNA purification step when performing RT-qPCR
Ingredients

Multi-Attribute Method (MAM) for quality control in therapeutic proteins manufacturing

Therapeutic proteins are a unique class of large molecule drugs that have far more complex structures than the small molecule drugs
Finance

Thermo Fisher and Symphogen continue biopharma collaboration

Since the collaboration began in 2018, Symphogen has adopted updated instruments and software aimed to improve data quality and processes
Manufacturing

Moderna and Thermo Fisher sign long-term manufacturing agreement

Thermo Fisher will provide dedicated capacity for fill-finish services, in addition to inspection, labelling and packaging
Finance

Thermo-Fisher adds Russia-based sales team

The change also provides customers in Russia with a connection to the wider customer community for peer-to-peer support, the company says
Finance

Thermo Fisher to build manufacturing facility in North Carolina

The investment is part of a strategy to build flexible and redundant production capacity in the US and across key global regions
Subscribe now